GLP-1/GLP-2 – Talk Bio

Actionable Insights Powered by AI

Zealand Pharma Pauses Development of GLP-1/GLP-2 Dual Agonist Dapiglutide for Obesity

4 weeks ago talkbio0Tagged Agonist, Clinical Development, Dapiglutide, drug market, GLP-1/GLP-2, Obesity, obesity therapy, petrelintide, pipeline management, Zealand Pharma

Zealand Pharma; dapiglutide; GLP-1/GLP-2 dual agonist; obesity therapy; clinical development; obesity drug market; pipeline management; petrelintide; survodutide

Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist

2 years ago talkbio0Tagged Agonist, Body Weight, Dosage, Effect, GLP-1/GLP-2, Lowest, Minimal, New Zealand

New Zealand, GLP-1/GLP-2 agonist, weight reduction, lowest doses, minimal effect.